Pharma Focus America

Johnson & Johnson Successfully Acquires Shockwave Medical

Saturday, June 01, 2024

Johnson & Johnson (NYSE: JNJ) has successfully finalized its acquisition of Shockwave Medical. Shockwave is now integrated into Johnson & Johnson and will function as a distinct business unit within Johnson & Johnson MedTech.

Johnson & Johnson, expressed, “By leveraging Innovative Medicine and MedTech, Johnson & Johnson is reshaping the course of cardiovascular disease, a major global health concern. We warmly welcome the Shockwave team to Johnson & Johnson and eagerly anticipate extending their innovative IVL technology to a broader spectrum of patients worldwide.”

Johnson & Johnson MedTech, remarked, “The completion of this acquisition marks a significant milestone in bolstering our leading position in the medtech sector. Shockwave’s unique solutions and promising pipeline present an exciting opportunity for Johnson & Johnson MedTech to introduce more advancements to patients in critical areas of unmet medical needs. We are enthusiastic about the prospects of collaborating with the Shockwave team and anticipate a prosperous journey together.”

This acquisition further solidifies Johnson & Johnson MedTech’s dominance in cardiovascular intervention. Shockwave offers the premier intravascular lithotripsy (IVL) platform for both coronary artery disease (CAD) and peripheral artery disease (PAD), augmenting Johnson & Johnson’s existing strengths in heart recovery (Abiomed) and electrophysiology (Biosense Webster), positioning it as a category leader across four major and high-growth medtech markets within cardiovascular intervention.

Shockwave is poised to become Johnson & Johnson MedTech’s thirteenth priority platform, characterized by annual sales exceeding $1 billion. The transaction is anticipated to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech. While Johnson & Johnson expects the transaction to enhance operating margin, it may slightly dilute adjusted earnings per share by approximately $0.10 in 2024 and around $0.17 in 2025 due to financing costs.

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024